Genomic Vision announced that it has signed an exclusive distribution agreement with AmCare Genomics Laboratory to market the FSHD diagnostic assay in China.
“We are thrilled to have acquired Genomic Vision’s technology and signed an exclusive distribution agreement for the FSHD diagnostic assay in China. Thanks to our large network and connections within the neurology and FSHD communities in China, we are confident in raising significant awareness among physicians and patients on the most powerful diagnostic test for FSHD,” commented Dr. Victor Wei Zhang, CEO of AmCare Genomics Laboratory.
“Following our distribution deal with APG Bio Ltd last June, this marketing agreement with AmCare represents a second major milestone in our global strategy to enter new markets in Asia. In China, it is estimated that 70,000 to 140,000 people are affected with FSHD. Moreover, the field of genomics and genetic testing is extremely developed, notably in large cities. We are convinced that our robust diagnostic technology will provide great benefits to families and patients. We look forward to deploying our FSHD solution in China and to strengthening our presence in the country through this valuable partnership,” added David Del Bourgo, Marketing & Sales Director of Genomic Vision.
Facioscapulohumeral muscular dystrophy (FSHD) is the third most prevalent muscular hereditary myopathy worldwide. This genetic disease manifests as atrophy and weakness in the face, shoulders, and ambulatory muscles. There is great variability in clinical severity, from a severe infantile form to individuals who remain asymptomatic throughout their lives. This autosomal dominant disease is thought to affect 1 in 10,000 to 1 in 20,000 people. The actual number of individuals with FSHD worldwide is 870,000, which could be significantly higher due to undiagnosed cases. About 70% of FSHD patients inherit the disease from a parent, while 30% of the cases are sporadic and associated to de novo mutations.
